The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities. Gynecol Oncol. 2018 Jan 31;: Authors: Moore KN, Mirza MR, Matulonis UA Abstract Niraparib is an oral poly(ADP ribose) polymerase (PARP) inhibitor that is currently approved by the United States Food and Drug Administration (US FDA) as well as recently approved by the European Medicines Agency (EMA) for the maintenance treatment of women with recurrent ovarian cancer who are in complete or partial response to platinum-based chemotherapy. The mechanisms of action of niraparib include inhibition of PARP enzymatic activity as well as increased formation of PARP-DNA complexes through "trapping" the PARP enzyme on damaged DNA. Phase I and III studies have demonstrated activity and benefit of niraparib in both BRCA mutated (BRCAm) and BRCA wild-type (BRCAwt) cancers. Phase I testing of niraparib established the maximally tolerated dose of 300mg by mouth (PO) daily, and the phase 3 ENGOT-OV16/NOVA study demonstrated the benefit of niraparib maintenance therapy compared to placebo after completion of and response to platinum-based chemotherapy in both BRCAm and BRCAwt ovarian cancer patient populations. Toxicities seen with niraparib include hematologic, gastrointestinal, fatigue, and cardiovascular. Hematologic toxicities include thrombocytopenia, anemia, neutropenia and leukopenia; upfront dose modification to 200mg niraparib for patients with baseline weight of ≤77kg a...
The thumbnail take on finasteride has been that it prevents prostate cancer but increases the risk for high-grade disease. A new study debunks the latter idea.Medscape Medical News
Smart technologies can sift through data to help the NHS spot diseases quicker, the PM is to say.
LONDON (Reuters) - Prime Minister Theresa May will call on Britain's health service, charities and artificial intelligence sector to work together to better identify patients with the early stages of cancer and stop thousands dying each year.
This article will discuss those efforts and results to date. PMID: 29766832 [PubMed - as supplied by publisher]
This study assessed the survival impact of combined surgery to the primary tumor and metastatic disease in the management of metastatic NSCLC. Stage IV NSCLC patients at presentation, diagnosed from 2004 to 2013 were identified from the SEER (Surveillance, Epidemiology, and End Results) database. Propensity-matched analysis was performed considering baseline characteristics (age, gender, race, histology, TN stage, and site of metastases). A total of 144,334 patients were identified. The median age group was 65-70 years, and 1139 patients (0.8% of the patients) have received surgical treatment to both the primary tumor...
In conclusion, NSUN2 is a potential independent prognostic marker and may be a potential therapeutic target in HNSCC. PMID: 29775108 [PubMed - in process]
The costs associated with a cancer diagnosis can add to a patient's stress, which can have a negative effect on outcome. Nurses can help by being prepared to discuss the financial aspects of care.Medscape Medical News
[The Conversation Africa] As cancer and other non-infectious diseases continue to rise all over the world it's become harder for scientists to find safe, effective treatments. In addition, bacteria are becoming more and more resistant to drugs and synthetic medicines have become harsher.
Abstract Hypoxia plays a crucial role in cancer progression, and it has great significance for monitoring hypoxic level in biosystems. Cancer stem cells (CSCs) represent a small population of tumour cells that regard as the key to seed tumours. The survival of CSCs depend on the tumour microenvironment, which is distinct region has the hypoxic property. Therefore, the detection of the hypoxic CSC niche plays a pivotal role in the destructing the 'soil' of CSCs, and eliminating CSCs population. Numerous one-photon excited fluorescent probes have been developed to indicate the hypoxic status in tumours through the d...
In this report, a hydrophilic probe in mesoporous pore (denoted as Fe3O4@mSiO2@G6P) was designed and prepared. By taking advantage of the excellent hydrophilicity and size-exclusion ability, we applied Fe3O4@mSiO2@G6P to capture glycopeptides from both horseradish peroxidase (HRP) and immunoglobulin (IgG) digests successfully. Moreover, a total of 39 and 25 endogenous glycopeptides were identified from healthy saliva and gastric saliva, respectively, indicating the great potential of this probe for the exploration of glycopeptidome biomarkers. PMID: 29776550 [PubMed - in process]
More News: Acute Leukemia | Acute Myeloid Leukemia | Anemia | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Chemotherapy | European Medicines Agency (EMA) | Food and Drug Administration (FDA) | Gastroenterology | Heart | Hematology | Hypertension | Immunotherapy | Leukemia | Myelodysplastic Syndrome | Oral Cancer | Ovarian Cancer | Ovaries | Study | Thrombocytopenia | Toxicology | USA Health | Women